Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
69 /100
COMPONENT-LIMITED
Score updated Aug 28, 2026

APUS — Apimeds Pharmaceuticals US, Inc. Dilution Risk Tracker

Track APUS dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track APUS — Get alerts when the score changes →

As of August 28, 2026, Apimeds Pharmaceuticals US, Inc. (APUS) has a DilutionWatch DilutionScore of 69/100, rated HIGH dilution risk. This is a component-limited score because one or more material inputs are unavailable or not applicable. Apimeds Pharmaceuticals US, Inc. has a market capitalization of $21.28M, 1.51M shares outstanding, 6 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
60
💰 Cash Runway
95
📊Float Risk
⚠️ Warrant Exposure
40
🔄 Convertible Debt
60

Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
model est. 42%
💰 Capital Raise model 55%
• Critical: only 2.4 months cash remaining
🔁 Convertible Conversion model 40%
• Significant convertible debt: 23% potential dilution
• Elevated convertible risk (60/100)
🔄 Reverse Split model est. 15%
• Only 2 months cash — financial pressure
🔔 Track APUS — Get forecast alerts →

Market Data

Market Cap$21.28M
Shares Outstanding1.51M
FloatN/A
Cash$1.78M
Debt$20.0K
Short InterestN/A

Institutional Holdings

QoQ: ↑ 37.6% shares (2026Q1 vs prior)
6 institutional holders · 544.7K shares
#1 Hemenway Trust Co LLC 274.0K shares
#2 VANGUARD CAPITAL MANAGEMENT LLC 191.9K shares
#3 GEODE CAPITAL MANAGEMENT, LLC 40.1K shares
+ 3 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest26.8K
Days to Cover1.0
% of FloatN/A
FINRA data as of Jul 31, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2025-12-31
xbrl XBRL CONVERTIBLE 2025-12-31
Full SEC filing analysis available with free account

Recent News

No recent news

Factual APUS Dilution Snapshot

Apimeds Pharmaceuticals US, Inc. (APUS) has a DilutionScore of 69/100, rated High dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track APUS Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking APUS — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations

Score Coverage Note